NeuroMetrix Inc. buy melinda
Startpreis
16.11.18
/
50%
9,29 €
Kursziel
30.10.19
11,73 €
Rendite (%)
-73,74 %
Endpreis
30.10.19
2,44 €
Zusammenfassung
Diese Einschätzung wurde am 30.10.19 mit einem Endkurs von 2,44 € beendet. Die BUY Einschätzung von melinda schloss mit einer Rendite von -73,74 %. melinda hat 50% Zuversicht bei dieser Einschätzung
Finanztrends
Rendite ohne Dividenden (%)
| Name | 1W | 1M | 1J | 3J |
|---|---|---|---|---|
| NeuroMetrix Inc. | - | - | - | - |
| iShares Core DAX® | -0,62 % | 1,08 % | 11,29 % | 16,44 % |
| iShares Nasdaq 100 | -4,50 % | -5,43 % | 22,17 % | 39,30 % |
| iShares Nikkei 225® | -2,56 % | -1,62 % | 7,26 % | 8,38 % |
| iShares S&P 500 | -1,71 % | -1,22 % | 22,55 % | 41,00 % |
Kommentare von melinda zu dieser Einschätzung
In der Diskussion NeuroMetrix Inc. diskutieren
SecteurEquipement, fournitures et distribution médicale
Designs and develops medical devices used for treatment of the neurological complications of diabetes
NeuroMetrix, Inc. is a healthcare company, which engages in the research, development, and trade of medical equipment and consumables.
It offers an over-the-counter wearable therapeutic device for chronic pain, the Quell Health Cloud, DPNCheck, and pain management devices to treat chronic pain, nerve diseases, and sleep disorder.
The company was founded by Shai N. Gozani in June 1996 and is headquartered in Waltham, MA.
NeuroMetrix, Inc. is a healthcare company, which engages in the research, development, and trade of medical equipment and consumables.
It offers an over-the-counter wearable therapeutic device for chronic pain, the Quell Health Cloud, DPNCheck, and pain management devices to treat chronic pain, nerve diseases, and sleep disorder.
The company was founded by Shai N. Gozani in June 1996 and is headquartered in Waltham, MA.
Nombre d'employés : 41 personnes.